The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform

Michael H Hsieh - One of the best experts on this subject based on the ideXlab platform.

  • ipse a parasite derived host immunomodulatory protein is a potential therapeutic for Hemorrhagic Cystitis
    American Journal of Physiology-renal Physiology, 2019
    Co-Authors: Evaristus C Mbanefo, Loc Le, Luke F Pennington, Justin I Odegaard, Theodore S Jardetzky, Abdulaziz Alouffi, Jude Akinwale, Franco H Falcone, Michael H Hsieh
    Abstract:

    Chemotherapy-induced Hemorrhagic Cystitis is characterized by bladder pain and voiding dysfunction caused by hemorrhage and inflammation. Novel therapeutic options to treat Hemorrhagic Cystitis are...

  • ipse a parasite derived host immunomodulatory protein is a promising therapeutic for Hemorrhagic Cystitis
    bioRxiv, 2018
    Co-Authors: Evaristus C Mbanefo, Loc Le, Luke F Pennington, Justin I Odegaard, Theodore S Jardetzky, Abdulaziz Alouffi, Jude Akinwale, Franco H Falcone, Michael H Hsieh
    Abstract:

    Chemotherapy-induced Hemorrhagic Cystitis is characterized by bladder pain and voiding dysfunction caused by hemorrhage and inflammation. Of currently available therapies, prophylactic 2-mercaptoethanesulfonic acid (MESNA) has limited efficacy and cannot treat pre-existing lesions. Therefore, novel therapeutic options to treat Hemorrhagic Cystitis are needed. We previously reported that systemic administration of the Schistosomiasis haematobium-derived protein H-IPSEH06 (IL-4-inducing principle from Schistosoma mansoni eggs), is superior to 3 doses of MESNA in alleviating Hemorrhagic Cystitis. Based on prior reports by others on S. mansoni IPSE and additional work by our group, we reasoned that H-IPSEH06 mediates its effects on Hemorrhagic Cystitis by binding IgE on basophils and inducing IL-4 expression, promoting urothelial proliferation, and translocating to the nucleus to modulate expression of genes implicated in relieving bladder dysfunction. We speculated that local bladder injection of the S. haematobium IPSE ortholog IPSEH03, hereafter called H-IPSEH03, might be more efficacious in preventing Hemorrhagic Cystitis compared to systemic administration of IPSEH06. We demonstrate herein that H-IPSEH03 is a promising therapeutic for the treatment of voiding dysfunction and bladder pain in Hemorrhagic Cystitis. Namely, it attenuates ifosfamide-induced increases in bladder wet weight in an IL-4-dependent fashion. H-IPSEH03 relieves Hemorrhagic Cystitis-associated allodynia. Finally, H-IPSEH03 drives increased urothelial cell proliferation. This indicates that IPSE induces bladder healing mechanisms, which suggests that it may be a novel non-opioid analgesic to treat bladder pain syndromes.

  • therapeutic exploitation of ipse a urogenital parasite derived host modulatory protein for chemotherapy induced Hemorrhagic Cystitis
    The FASEB Journal, 2018
    Co-Authors: Evaristus C Mbanefo, Loc Le, Luke F Pennington, Justin I Odegaard, Theodore S Jardetzky, Abdulaziz Alouffi, Franco H Falcone, Michael H Hsieh
    Abstract:

    Chemotherapy-induced Hemorrhagic Cystitis (CHC) can be difficult to manage. Prior work suggests that IL-4 alleviates ifosfamide-induced Hemorrhagic Cystitis (IHC), but systemically administered IL-...

  • review of advances in uroprotective agents for cyclophosphamide and ifosfamide induced Hemorrhagic Cystitis
    Urology, 2017
    Co-Authors: Ethan L Matz, Michael H Hsieh
    Abstract:

    Cyclophosphamide and ifosfamide are widely used drugs for malignancies and rheumatologic conditions. One of the most significant adverse reactions to these drugs is Hemorrhagic Cystitis. Mesna is the most widely used uroprotective agent that acts to neutralize the caustic metabolite, acrolein, responsible for induction of Hemorrhagic Cystitis. However, mesna is not a perfect alternative, and studies since its discovery have investigated the use of alternative drugs and adjuncts to increase mesna's efficacy. This review details some of the recent work into novel uroprotective agents for drug-induced Hemorrhagic Cystitis.

Zahi Makhuli - One of the best experts on this subject based on the ideXlab platform.

  • hyperbaric oxygen therapy for radiation induced Hemorrhagic Cystitis
    The Journal of Urology, 1999
    Co-Authors: Ranjiv Mathews, Natarajan Rajan, Laura Josefson, Enrico M Camporesi, Zahi Makhuli
    Abstract:

    AbstractPurpose: Radiation therapy has been used successfully to treat pelvic malignancy but morbidity from Hemorrhagic Cystitis remains a major long-term sequela in 1 to 2% of patients. Obliterative endarteritis secondary to ionizing radiation leads to tissue hypoxia and poor healing. Hyperbaric oxygen therapy has been demonstrated to improve angiogenesis and promote healing in radiation injured tissue, including the bladder. We describe the treatment and long-term followup of a cohort of patients treated with hyperbaric oxygen for Hemorrhagic Cystitis.Materials and Methods: A total of 17 patients (mean age 62 years) with Hemorrhagic Cystitis received hyperbaric oxygen following failure of standard treatment modalities. Hyperbaric oxygen was administered on a once daily schedule (mean number of treatments 14) until hematuria resolved. Followup ranged from 9 to 60 months (mean 21).Results: Hematuria resolved completely in 11 of 17 patients (64%), 2 had only residual microscopic hematuria, 2 had improvemen...

Benjamin T Davis - One of the best experts on this subject based on the ideXlab platform.

  • bk virus associated Hemorrhagic Cystitis in a human immunodeficiency virus infected patient
    Clinical Infectious Diseases, 2002
    Co-Authors: Dan H Barouch, William C Faquin, Yiping Chen, Igor J Koralnik, Gregory K Robbins, Benjamin T Davis
    Abstract:

    BK virus-associated Hemorrhagic Cystitis is a common clinical problem in bone marrow transplant recipients but is considered rare in other immunosuppressed patient populations. We describe a human immunodeficiency virus-infected patient with non-Hodgkin's lymphoma in whom BK virus-associated Hemorrhagic Cystitis developed; viruria was quantitated in urine by immunocytochemistry, and the patient showed no response to cidofovir.

  • BK Virus–Associated Hemorrhagic Cystitis in a Human Immunodeficiency Virus–Infected Patient
    Clinical Infectious Diseases, 2002
    Co-Authors: Dan H Barouch, William C Faquin, Yiping Chen, Igor J Koralnik, Gregory K Robbins, Benjamin T Davis
    Abstract:

    BK virus-associated Hemorrhagic Cystitis is a common clinical problem in bone marrow transplant recipients but is considered rare in other immunosuppressed patient populations. We describe a human immunodeficiency virus-infected patient with non-Hodgkin's lymphoma in whom BK virus-associated Hemorrhagic Cystitis developed; viruria was quantitated in urine by immunocytochemistry, and the patient showed no response to cidofovir.

Dana W Giel - One of the best experts on this subject based on the ideXlab platform.

  • risk factors associated with severity and outcomes in pediatric patients with Hemorrhagic Cystitis
    The Journal of Urology, 2016
    Co-Authors: Derrick L Johnston, Elleson Schurtz, Elizabeth Tourville, Tamekia L Jones, Allison Boemer, Dana W Giel
    Abstract:

    Purpose: Hemorrhagic Cystitis is a complication of treatment of pediatric cancer with considerable variation in severity and morbidity. This study presents an analysis of Hemorrhagic Cystitis severity and treatment outcomes in a large pediatric population.Materials and Methods: Patients with Hemorrhagic Cystitis treated at St. Jude Children's Research Hospital® were identified from 1990 to 2010. Demographic data were gathered along with information pertaining to initial primary diagnosis, Hemorrhagic Cystitis diagnosis and treatment, and mortality. Statistical analyses were performed to evaluate associations between risk factors and severity of Hemorrhagic Cystitis as well as treatment outcomes.Results: Of the 285 patients who met inclusion criteria 54% were male. Mean age was 11.41 years. Mean time from initial primary diagnosis to Hemorrhagic Cystitis onset was 29 months. Noninvasive treatment was performed in 246 patients (86%) and operative intervention was required in 14 (4.9%). Bivariate analysis de...

  • Risk Factors Associated with Severity and Outcomes in Pediatric Patients with Hemorrhagic Cystitis.
    The Journal of urology, 2016
    Co-Authors: Derrick Johnston, Elleson Schurtz, Elizabeth Tourville, Allison Boemer, Tamekia Jones, Dana W Giel
    Abstract:

    Hemorrhagic Cystitis is a complication of treatment of pediatric cancer with considerable variation in severity and morbidity. This study presents an analysis of Hemorrhagic Cystitis severity and treatment outcomes in a large pediatric population. Patients with Hemorrhagic Cystitis treated at St. Jude Children's Research Hospital® were identified from 1990 to 2010. Demographic data were gathered along with information pertaining to initial primary diagnosis, Hemorrhagic Cystitis diagnosis and treatment, and mortality. Statistical analyses were performed to evaluate associations between risk factors and severity of Hemorrhagic Cystitis as well as treatment outcomes. Of the 285 patients who met inclusion criteria 54% were male. Mean age was 11.41 years. Mean time from initial primary diagnosis to Hemorrhagic Cystitis onset was 29 months. Noninvasive treatment was performed in 246 patients (86%) and operative intervention was required in 14 (4.9%). Bivariate analysis demonstrated that pelvic radiation therapy (p = 0.0002), any radiation therapy (p = 0.005), acute lymphocytic leukemia (p = 0.01), bone marrow transplantation (p = 0.0225), cyclophosphamide exposure (p = 0.0419) and BK virus positivity (p = 0.0472) were predictors of higher grade Hemorrhagic Cystitis. Factors correlating with the need for invasive management on bivariate analysis included pelvic radiation therapy (p = 0.0266), bone marrow transplantation (p = 0.0007), hematological malignancy (p = 0.0066), ifosfamide exposure (p = 0.0441) and male gender (p = 0.0383). Multivariate analysis showed independent effects of pelvic radiation therapy (p = 0.001) and delayed onset of Hemorrhagic Cystitis (p = 0.0444). Severity of Hemorrhagic Cystitis and failure of noninvasive management correlate with several identifiable risk factors. Prospective identification of patients with these risk factors may allow for targeted early intervention in those at highest risk. Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Derrick L Johnston - One of the best experts on this subject based on the ideXlab platform.

  • risk factors associated with severity and outcomes in pediatric patients with Hemorrhagic Cystitis
    The Journal of Urology, 2016
    Co-Authors: Derrick L Johnston, Elleson Schurtz, Elizabeth Tourville, Tamekia L Jones, Allison Boemer, Dana W Giel
    Abstract:

    Purpose: Hemorrhagic Cystitis is a complication of treatment of pediatric cancer with considerable variation in severity and morbidity. This study presents an analysis of Hemorrhagic Cystitis severity and treatment outcomes in a large pediatric population.Materials and Methods: Patients with Hemorrhagic Cystitis treated at St. Jude Children's Research Hospital® were identified from 1990 to 2010. Demographic data were gathered along with information pertaining to initial primary diagnosis, Hemorrhagic Cystitis diagnosis and treatment, and mortality. Statistical analyses were performed to evaluate associations between risk factors and severity of Hemorrhagic Cystitis as well as treatment outcomes.Results: Of the 285 patients who met inclusion criteria 54% were male. Mean age was 11.41 years. Mean time from initial primary diagnosis to Hemorrhagic Cystitis onset was 29 months. Noninvasive treatment was performed in 246 patients (86%) and operative intervention was required in 14 (4.9%). Bivariate analysis de...